LOQTORZI

This brand name is authorized in United States

Active ingredients

The drug LOQTORZI contains one active pharmaceutical ingredient (API):

1 Toripalimab UNII 8JXN261VVA - TORIPALIMAB

Toripalimab is a recombinant humanized programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpoint inhibitor. Toripalimab is used for the treatment of melanoma and nasopharyngeal carcinoma. Read about Toripalimab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LOQTORZI Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FF13		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: US	FDA, National Drug Code	Identifier(s): 70114-340, 83718-000